An active comparator study has shown that injections of daclizumab high-yield process (HYP), administered every 4 weeks, are more effective than weekly IFN-β1a injections at reducing relapse rates in patients with multiple sclerosis. However, the two drugs were comparable in terms of their effects on disability progression, and adverse events were more common in the daclizumab HYP group than in the IFN-β1a group, indicating that the choice of treatment is likely to be dictated by a variety of factors in addition to efficacy.
References
Kappos, L. et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 373, 1418–1428 (2015)
Rights and permissions
About this article
Cite this article
Daclizumab HYP shows superiority to IFN-β1a for reducing relapses in multiple sclerosis. Nat Rev Neurol 11, 612 (2015). https://doi.org/10.1038/nrneurol.2015.186
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2015.186